Exagen Inc (NASDAQ:XGN) Surpasses Revenue Estimates in Q2 2025 Despite Wider Loss, Shares Rally in Pre-Market Trading

Exagen Inc (NASDAQ:XGN), a commercial-stage diagnostics company specializing in autoimmune testing solutions, reported its second-quarter 2025 financial results, surpassing revenue expectations but posting a wider-than-expected loss per share. The market reaction has been notably positive, with shares rising sharply in pre-market trading, suggesting investor optimism despite the earnings miss.

Key Financial Highlights vs. Estimates

• Revenue: Exagen reported Q2 2025 revenue of $17.2 million, exceeding analyst estimates of $16.46 million, reflecting a 4.5% beat.
• Earnings Per Share (EPS): The company posted a loss of $0.18 per share, worse than the consensus estimate of a $0.14 loss, indicating higher-than-anticipated expenses or investment in growth initiatives.

Market Reaction

The stock surged 6.77% in pre-market trading, signaling strong investor confidence following the revenue beat. Over the past month, shares have gained 5.57%, with a modest uptick of 6.03% in the last week, suggesting sustained bullish sentiment ahead of the earnings release.

Forward-Looking Estimates vs. Press Release Outlook

While the press release did not provide explicit forward guidance, analysts project:

• Q3 2025 Revenue: $16.75 million
• Q3 2025 EPS: -$0.14
• Full-Year 2025 Revenue: $66.17 million
• Full-Year 2025 EPS: -$0.57

The lack of company-provided guidance leaves investors reliant on analyst expectations, but the revenue outperformance in Q2 may lead to upward revisions in future estimates.

Press Release Summary

Exagen highlighted its continued progress in commercializing its AVISE CTD and AVISE Lupus diagnostic tests, which are gaining traction among rheumatologists. The company emphasized its role in improving differential diagnosis for autoimmune diseases, though no new clinical or regulatory milestones were disclosed in this update.

For a deeper dive into Exagen’s earnings history and future estimates, visit the earnings and estimates page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.